Ketamine and rapid-acting antidepressants: a window into a new neurobiology for mood disorder therapeutics.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Annual Review of Medicine

• Publication date

  2015-01-14

• Fields of study

  Medicine

• Identifiers
  DOI 10.1146/annurev-med-053013-062946PMID 25341010PMCID PMC4428310
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Augmentation of response and remission to serial intravenous subanesthetic ketamine in treatment resistant depression.

  2014cited by this paper
• Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.

  2014cited by this paper
• Ketamine infusions for treatment resistant depression: a series of 28 patients treated weekly or twice weekly in an ECT clinic

  2014cited by this paper
• A randomized controlled trial of intranasal ketamine in major depressive disorder.

  2014cited by this paper
• Do the dissociative side effects of ketamine mediate its antidepressant effects?

  2014cited by this paper
• Plasma brain derived neurotrophic factor (BDNF) and response to ketamine in treatment-resistant depression.

  2014cited by this paper
• Acute Antidepressant Effects of Intramuscular Versus Intravenous Ketamine

  2014cited by this paper
• Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds.

  2014cited by this paper
• REDD1 is essential for stress-induced synaptic loss and depressive behavior

  2014cited by this paper
• EFFECTS OF KETAMINE ON EXPLICIT AND IMPLICIT SUICIDAL COGNITION: A RANDOMIZED CONTROLLED TRIAL IN TREATMENT‐RESISTANT DEPRESSION

  2014cited by this paper
• The effects of subanesthetic ketamine infusions on motivation to quit and cue-induced craving in cocaine-dependent research volunteers.

  2014cited by this paper
• Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression.

  2013cited by this paper
• Stress-induced anhedonia is associated with hypertrophy of medium spiny neurons of the nucleus accumbens

  2013cited by this paper
• Relationship of ketamine's antidepressant and psychotomimetic effects in unipolar depression.

  2013cited by this paper
• A 12-month naturalistic observation of three patients receiving repeat intravenous ketamine infusions for their treatment-resistant depression.

  2013cited by this paper
• Nuclear calcium signalling in the regulation of brain function

  2013cited by this paper
• Randomized Controlled Crossover Trial of Ketamine in Obsessive-Compulsive Disorder: Proof-of-Concept

  2013cited by this paper
• NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease

  2013cited by this paper
• Vitamin B12 Level may be Related to the Efficacy of Single Ketamine Infusion in Bipolar Depression

  2013cited by this paper
• Cortical energy demands of signaling and nonsignaling components in brain are conserved across mammalian species and activity levels

  2013cited by this paper
• Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder.

  2013influential reference
• Scopolamine rapidly increases mammalian target of rapamycin complex 1 signaling, synaptogenesis, and antidepressant behavioral responses.

  2013cited by this paper
• Serial infusions of low-dose ketamine for major depression

  2013cited by this paper
• Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.

  2013cited by this paper
• Single ketamine infusion in bipolar depression resistant to antidepressants: are neurotrophins involved?

  2013cited by this paper
• Repeated S‐ketamine Infusions in Therapy Resistant Depression: A Case Series

  2013cited by this paper
• Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond.

  2013influential reference
• Ketamine Pharmacology: An Update (Pharmacodynamics and Molecular Aspects, Recent Findings)

  2013cited by this paper
• GSK-3 Inhibition Potentiates the Synaptogenic and Antidepressant-Like Effects of Subthreshold Doses of Ketamine

  2013cited by this paper
• Homeostatic synaptic plasticity: local and global mechanisms for stabilizing neuronal function.

  2012cited by this paper
• Lack of effect of ketamine on cortical glutamate and glutamine in healthy volunteers: a proton magnetic resonance spectroscopy study

  2012cited by this paper
• Relationship of ketamine's plasma metabolites with response, diagnosis, and side effects in major depression.

  2012cited by this paper
• Synaptic potentiation is critical for rapid antidepressant response to ketamine in treatment-resistant major depression.

  2012cited by this paper
• Ketamine use: a review.

  2012cited by this paper
• Effects of ketamine in treatment-refractory obsessive-compulsive disorder.

  2012cited by this paper
• Decreased Expression of Synapse-Related Genes and Loss of Synapses in Major Depressive Disorder

  2012cited by this paper
• Family history of alcohol dependence and antidepressant response to an N-methyl-D-aspartate antagonist in bipolar depression.

  2012cited by this paper
• Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial.

  2012cited by this paper
• An investigation of amino-acid neurotransmitters as potential predictors of clinical improvement to ketamine in depression.

  2012cited by this paper
• Ketamine for depression: where do we go from here?

  2012cited by this paper
• Repeated stress causes cognitive impairment by suppressing glutamate receptor expression and function in prefrontal cortex.

  2012cited by this paper
• On the safety and benefits of repeated intravenous injections of ketamine for depression.

  2012cited by this paper
• mTOR activation is required for the antidepressant effects of mGluR₂/₃ blockade.

  2012cited by this paper
• Brain-derived neurotrophic factor Val66Met allele impairs basal and ketamine-stimulated synaptogenesis in prefrontal cortex.

  2012cited by this paper
• Ketamine effects on brain GABA and glutamate levels with 1H-MRS: relationship to ketamine-induced psychopathology

  2012influential reference
• ¹H-[¹³C]-nuclear magnetic resonance spectroscopy measures of ketamine's effect on amino acid neurotransmitter metabolism.

  2012cited by this paper
• Synaptic mechanisms underlying rapid antidepressant action of ketamine.

  2012cited by this paper
• Rapid Response with Ketamine on Suicidal Cognition in Resistant Depression

  2012cited by this paper
• Synaptic Dysfunction in Depression: Potential Therapeutic Targets

  2012cited by this paper
• Rapid decrease in depressive symptoms with an N-methyl-d-aspartate antagonist in ECT-resistant major depression.

  2011cited by this paper
• Mechanisms underlying NMDA receptor synaptic/extrasynaptic distribution and function.

  2011cited by this paper
• The stressed synapse: the impact of stress and glucocorticoids on glutamate transmission

  2011influential reference
• Grand challenges in global mental health

  2011cited by this paper
• Pharmacological Blockade of Serotonin 5-HT7 Receptor Reverses Working Memory Deficits in Rats by Normalizing Cortical Glutamate Neurotransmission

  2011cited by this paper
• Too many cooks? Intrinsic and synaptic homeostatic mechanisms in cortical circuit refinement.

  2011cited by this paper
• Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure.

  2011cited by this paper
• NMDA Receptor Blockade at Rest Triggers Rapid Behavioural Antidepressant Responses

  2011cited by this paper
• A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department.

  2011cited by this paper
• The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [(1)H]-MRS.

  2011influential reference
• Involvement of AMPA receptor in both the rapid and sustained antidepressant-like effects of ketamine in animal models of depression.

  2011cited by this paper
• Mechanisms of synapse and dendrite maintenance and their disruption in psychiatric and neurodegenerative disorders.

  2010cited by this paper
• Potential Psychiatric Applications of Metabotropic Glutamate Receptor Agonists and Antagonists

  2010cited by this paper
• Metabotropic glutamate receptors: physiology, pharmacology, and disease.

  2010cited by this paper
• Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders

  2010cited by this paper
• Meta-analysis of the BDNF Val66Met polymorphism in major depressive disorder: effects of gender and ethnicity

  2010cited by this paper
• Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder.

  2010cited by this paper
• A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression.

  2010cited by this paper
• mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists

  2010cited by this paper
• Ubiquitination in postsynaptic function and plasticity.

  2010cited by this paper
• Anterior Cingulate Desynchronization and Functional Connectivity with the Amygdala During a Working Memory Task Predict Rapid Antidepressant Response to Ketamine

  2010cited by this paper
• The mood-improving actions of antidepressants do not depend on neurogenesis but are associated with neuronal remodeling

  2009cited by this paper
• Bipolar and major depressive disorder: neuroimaging the developmental-degenerative divide.

  2009cited by this paper
• Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression.

  2009cited by this paper
• Family history of alcohol dependence and initial antidepressant response to an N-methyl-D-aspartate antagonist.

  2009cited by this paper
• Brain-derived neurotrophic factor and initial antidepressant response to an N-methyl-D-aspartate antagonist.

  2009influential reference
• Increased anterior cingulate cortical activity in response to fearful faces: a neurophysiological biomarker that predicts rapid antidepressant response to ketamine.

  2009cited by this paper
• Spectral simplification for resolved glutamate and glutamine measurement using a standard STEAM sequence with optimized timing parameters at 3, 4, 4.7, 7, and 9.4T

  2008cited by this paper
• Synaptic Plasticity: Multiple Forms, Functions, and Mechanisms

  2008cited by this paper
• Glutamate and the neural basis of the subjective effects of ketamine: a pharmaco-magnetic resonance imaging study.

  2008cited by this paper
• Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications.

  2008cited by this paper
• Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors.

  2008cited by this paper
• From inflammation to sickness and depression: when the immune system subjugates the brain

  2008cited by this paper
• Clozapine and Haloperidol Differently Suppress the MK-801-Increased Glutamatergic and Serotonergic Transmission in the Medial Prefrontal Cortex of the Rat

  2007cited by this paper
• Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial.

  2006cited by this paper
• Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report.

  2006cited by this paper
• A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.

  2006cited by this paper
• A neurotrophic model for stress-related mood disorders.

  2006influential reference
• Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication.

  2005cited by this paper
• Effects of ketamine on anterior cingulate glutamate metabolism in healthy humans: a 4-T proton MRS study.

  2005influential reference
• Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects

  2005cited by this paper
• Recovery after chronic stress fails to reverse amygdaloid neuronal hypertrophy and enhanced anxiety-like behavior.

  2004cited by this paper
• ECOVERY AFTER CHRONIC STRESS FAILS TO REVERSE MYGDALOID NEURONAL HYPERTROPHY AND ENHANCED NXIETY-LIKE BEHAVIOR

  2004cited by this paper
• Onset and Early Behavioral Effects of Pharmacologically Different Antidepressants and Placebo in Depression

  2004cited by this paper
• Altered NMDA glutamate receptor antagonist response in individuals with a family vulnerability to alcoholism.

  2004cited by this paper
• Effects of NRA0045, a novel potent antagonist at dopamine D4, 5-HT2A, and α1 adrenaline receptors, and NRA0160, a selective D4 receptor antagonist, on phencyclidine-induced behavior and glutamate release in rats

  2003cited by this paper
• The Yin and Yang of NMDA receptor signalling.

  2003cited by this paper
• Effects of ketamine and N-methyl-D-aspartate on glutamate and dopamine release in the rat prefrontal cortex: modulation by a group II selective metabotropic glutamate receptor agonist LY379268.

  2003cited by this paper
• Altered NMDA Glutamate Receptor Antagonist Response in Recovering Ethanol-Dependent Patients

  2003cited by this paper
• Control of synaptic strength by glial TNFalpha.

  2002cited by this paper
• Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists.

  2000cited by this paper

• Neurobiology and neuropharmacology of zebrafish social behavior.

  2026cites this paper
• Fast-acting antidepressants trigger presynaptic BDNF release and structural plasticity at mouse mossy fiber-CA3 synapses

  2026cites this paper
• Alterations in NMDA and AMPA Receptor Subunit Gene Expression in the Prefrontal Cortex of Rats from Different Age Groups in a Model of Depressive-Like Behavior

  2025cites this paper
• Recent advances in rapid-acting antidepressants

  2025cites this paper
• Genetics and Neurobiology of Treatment-Resistant Depression—A Review

  2025cites this paper
• Human Service Professionals’, Educators’, and Students’ Attitudes Toward Psychedelics and Psychedelic Therapy

  2025cites this paper
• New Directions in Neurosteroid Therapeutics in Neuropsychiatry.

  2025cites this paper
• LSD: Mechanisms and Relevance to the Treatment of Depression.

  2025cites this paper
• Acute effects of intranasal esketamine application on thalamic structures in healthy individuals

  2025cites this paper
• Novel and emerging anesthetic drugs for the treatments of major depression: a comprehensive review of efficacy, mechanism, and outlook

  2025cites this paper
• Unfolding States of Mind: A Dissociative-Psychedelic Model of Ketamine-Assisted Psychotherapy in Palliative Care

  2025cites this paper
• The Effects of Psychotherapy on Single and Repeated Ketamine Infusion(s) Therapy for Treatment-Resistant Depression: The Convergence of Molecular and Psychological Treatment

  2025cites this paper
• Serotonergic psychedelics for depression: A comprehensive overview.

  2025cites this paper
• Exploring the Different Impacts of Ketamine on Neurotrophic Factors and Inflammatory Parameters in a Cecal Ligation and Puncture-Induced Sepsis Model

  2025cites this paper
• Anxiety in Patients with Preexisting Depression and Anxiety Undergoing Total Hip Arthroplasty

  2025cites this paper
• Explainable AI-driven precision clinical trial enrichment: demonstration of the NetraAI platform with a phase II depression trial

  2025cites this paper
• Ketamine administration during adolescence impairs synaptic integration and inhibitory synaptic transmission in the adult dentate gyrus.

  2025cites this paper
• Association of escitalopram-induced shifts in gut microbiota and sphingolipid metabolism with depression-like behavior in wistar-kyoto rats

  2025cites this paper
• Network localization of functional brain changes associated with ketamine's therapeutic effects in depression.

  2025cites this paper
• The Connectomic Glutamate Framework for Depression: Bridging Molecular Plasticity and Network Reorganization

  2025cites this paper
• Safety in treatment: Classical pharmacotherapeutics and new avenues for addressing maternal depression and anxiety during pregnancy.

  2025cites this paper
• (2R,6R)‐hydroxynorketamine prevents opioid abstinence‐related negative affect and stress‐induced reinstatement in mice

  2025cites this paper
• Influência dos metabólitos glutamatérgicos no transtorno depressivo: uma revisão integrativa

  2025cites this paper
• Selective transcriptomic recovery by (2R,6R)-hydroxynorketamine in opioid-abstinent mice: Machine learning identifies predictive biomarkers

  2025cites this paper
• Ketamine for Depression, but at What Cost? A Review of Ketamine's Neurotoxic Effects From Preclinical and Human Studies.

  2025cites this paper
• A comparative assessment of the antidepressant efficacy of ketamine, psilocybin, and fluoxetine in a chronic stress model

  2025cites this paper
• Nanotechnology-Enhanced MicroRNAs for Improved Diagnosis and Treatment of Major Depressive Disorder: A Comprehensive Review

  2025cites this paper
• Effect of low-dose esketamine on postoperative quality of recovery in total laparoscopic hysterectomy: a randomized controlled trial

  2025cites this paper
• [Mechanisms of action and therapeutic perspectives of LSD: Current status].

  2025cites this paper
• Ketamine for unipolar depression: A systematic review of efficacy and safety

  2025influential citation
• Intranasal racemic ketamine maintenance therapy for patients with treatment-resistant depression: a naturalistic feasibility study

  2025cites this paper
• Safety and efficacy of ketamine for the treatment of patients with alcohol use disorder: a systematic review

  2025cites this paper
• Neural Network of Alpha Rhythm rs-EEG Activity for the Assessment of Consciousness in Psychopathology

  2025cites this paper
• D-arabinose acts as antidepressant by activating the ACSS2-PPARγ/TFEB axis and CRTC1 transcription.

  2024cites this paper
• Elevated neuron specific enolase levels in post-traumatic stress disorder

  2024cites this paper
• The neural basis of neuropsychiatric symptoms in Alzheimer’s disease

  2024cites this paper
• A contemporary analysis of the effects of neuroplasticity on well-being

  2024cites this paper
• Effects of Ketamine vs. Midazolam in Adolescent Treatment Resistant Depression

  2024cites this paper
• Intravenous ketamine versus electroconvulsive therapy for major depressive disorder or bipolar depression: A meta-analysis of randomized controlled trials.

  2024cites this paper
• An evaluation of the efficacy and side effects of a single dose of ketamine in major depressive disorder.

  2024cites this paper
• Ketamine Potentiates AMPA Receptor-mediated Activity in the Somatosensory Cortex.

  2024cites this paper
• Neuroplasticity and Mechanisms of Action of Acute and Chronic Treatment with Antidepressants in Preclinical Studies

  2024cites this paper
• Are ketamine and its enantiomers the answer to treatment-refractory depression?

  2024cites this paper
• Distinct synaptic mechanisms drive the behavioral response to acute stress and rapid correction by ketamine

  2024cites this paper
• Positive Effect of 6-Gingerol on Functional Plasticity of Microglia in a rat Model of LPS-induced Depression

  2024cites this paper
• Mechanisms of Differential Sensitivity to Ethanol-Induced Apoptosis in Mouse Spinal Cord at Different Developmental Stages—Akt/GSK Signaling and BAX

  2024cites this paper
• Experiences of Awe Mediate Ketamine’s Antidepressant Effects: Findings From a Randomized Controlled Trial in Treatment-Resistant Depression

  2024cites this paper
• Perspectives in treatment-resistant depression: esketamine and electroconvulsive therapy

  2024cites this paper
• Placebo stimulates neuroplasticity in depression: implications for clinical practice and research

  2024cites this paper
• Psychedelics for acquired brain injury: a review of molecular mechanisms and therapeutic potential

  2024cites this paper
• Ketamine potentiates a central glutamatergic presynapse

  2024cites this paper
• Exploring effects and experiences of ketamine in group couples therapy

  2024cites this paper
• Effect of ketamine on task-based functional magnetic resonance imaging findings in major depressive disorder: A mini-review.

  2024cites this paper
• FMOD Alleviates Depression-Like Behaviors by Targeting the PI3K/AKT/mTOR Signaling After Traumatic Brain Injury

  2024cites this paper
• Simvastatin ameliorates synaptic plasticity impairment in chronic mild stress-induced depressed mice by modulating hippocampal NMDA receptor

  2023cites this paper
• A Study of Brain Function Characteristics of Service Members at High Risk for Accidents in the Military

  2023cites this paper
• The possible place for psychedelics in pharmacotherapy of mental disorders

  2023cites this paper
• The effect of ketamine on synaptic mistuning induced by impaired glutamate reuptake

  2023cites this paper
• Antidepressants bind to cholesterol-interaction motif of TRKB neurotrophin receptor

  2023influential citation
• EXPLORING THE EFFICACY OF PSYCHOTROPIC DRUG COMBINATIONS FOR COVID-19 DEPRESSION

  2023cites this paper
• Ketamine-Assisted Psychodynamic Psychotherapy.

  2023cites this paper
• Predicting efficacy of sub-anesthetic ketamine/esketamine i.v. dose during course of cesarean section for PPD prevention, utilizing traditional logistic regression and machine learning models.

  2023cites this paper
• Cognitive impairment and factors influencing depression in adolescents with suicidal and self-injury behaviors: a cross-sectional study

  2023cites this paper
• Biomarkers in Psychiatric Drug Development: From Precision Medicine to Novel Therapeutics.

  2023cites this paper
• REPEATED DOSES OF SUBCUTANEOUS ESKETAMINE IN PATIENTS WITH TREATMENT-RESISTANT DEPRESSION: CASE SERIES IN A GENERAL HOSPITAL IN SOUTHERN BRAZIL

  2023cites this paper
• The potential of ketamine for posttraumatic stress disorder: a review of clinical evidence

  2023cites this paper
• Ketamine and its metabolite 2R,6R‐hydroxynorketamine promote ocular dominance plasticity and release tropomyosin‐related kinase B from inhibitory control without reducing perineuronal nets enwrapping parvalbumin interneurons

  2023cites this paper
• Switching from parenteral to oral formulation of ketamine in the management of severe depressive episode

  2023cites this paper
• GluCEST Imaging and Structural Alterations of the Bilateral Hippocampus in First‐Episode and Early‐Onset Major Depression Disorder

  2023cites this paper
• Berberine ameliorates depression-like behaviors in mice via inhibiting NLRP3 inflammasome-mediated neuroinflammation and preventing neuroplasticity disruption

  2023cites this paper
• Rapid neuroplasticity changes and response to intravenous ketamine: a randomized controlled trial in treatment-resistant depression

  2023cites this paper
• GABAergic neurons in the nucleus accumbens core mediate the antidepressant effects of sevoflurane.

  2023cites this paper
• (2R,6R)-hydroxynorketamine facilitates extinction and prevents emotional impairment and stress-induced reinstatement in morphine abstinent mice

  2023cites this paper
• Perspectives on agmatine neurotransmission in acute and chronic stress-related conditions.

  2023cites this paper
• Therapeutic doses of ketamine acutely attenuate the aversive effect of losses during decision-making

  2023cites this paper
• The Psychedelic Future of Post-Traumatic Stress Disorder Treatment

  2023cites this paper
• The effect of Ketamine on delta-range coupling between prefrontal cortex and hippocampus supported by respiratory rhythmic input from the olfactory bulb.

  2022cites this paper
• S-Ketamine Oral Thin Film—Part 1: Population Pharmacokinetics of S-Ketamine, S-Norketamine and S-Hydroxynorketamine

  2022cites this paper
• A Pilot Study of Ketamine Infusion after Suicide Attempt: New Frontiers in Treating Acute Suicidality in a Real-World Medical Setting

  2022cites this paper
• Molecular Basis Underlying the Therapeutic Potential of Vitamin D for the Treatment of Depression and Anxiety

  2022cites this paper
• Antidepressant properties of psilocybin might be related to changes in sleep

  2022cites this paper
• Molecular mechanisms underlying the N-methyl-d-aspartate receptor antagonists: Highlighting their potential for transdiagnostic therapeutics.

  2022cites this paper
• Electrophysiological phenotypes of suicidality predict prolonged response to oral ketamine treatment.

  2022cites this paper
• Astrocyte reactivation in medial prefrontal cortex contributes to obesity-promoted depressive-like behaviors

  2022cites this paper
• Rapid-Onset Antidepressant-Like Effect of Nelumbinis semen in Social Hierarchy Stress Model of Depression

  2022cites this paper
• Effects of stress on endophenotypes of suicide across species: A role for ketamine in risk mitigation

  2022cites this paper
• Potential of Heterogeneous Compounds as Antidepressants: A Narrative Review

  2022cites this paper
• Dysfunctional Heteroreceptor Complexes as Novel Targets for the Treatment of Major Depressive and Anxiety Disorders

  2022cites this paper
• Design of fast-onset antidepressant by dissociating SERT from nNOS in the DRN

  2022cites this paper
• Role of mTOR1 signaling in the antidepressant effects of ketamine and the potential of mTORC1 activators as novel antidepressants.

  2022cites this paper
• Ketamine and its metabolite 2R,6R-hydroxynorketamine promote ocular dominance plasticity and release TRKB from inhibitory control without changing perineuronal nets enwrapping parvalbumin interneurons

  2022cites this paper
• The ventromedial prefrontal cortex and emotion regulation: lost in translation?

  2022cites this paper
• Editorial: The glutamate hypothesis of mood disorders: Neuroplasticity processes, clinical features, treatment perspectives

  2022cites this paper
• Glutamate Efflux across the Blood–Brain Barrier: New Perspectives on the Relationship between Depression and the Glutamatergic System

  2022cites this paper
• A Novel, Brief, Fully Automated Intervention to Extend the Antidepressant Effect of a Single Ketamine Infusion: A Randomized Clinical Trial.

  2022cites this paper
• The neuroprotective and neuroplastic potential of glutamatergic therapeutic drugs in bipolar disorder.

  2022cites this paper
• Imaging the effect of ketamine on synaptic density (SV2A) in the living brain

  2022cites this paper
• The Effects of Acute and Repeated Administration of Ketamine on Memory, Behavior, and Plasma Corticosterone Levels in Female Mice.

  2022cites this paper
• Targeted effects of ketamine on perceptual expectation during mediated learning in rats

  2022cites this paper
• Acute Ketamine Facilitates Fear Memory Extinction in a Rat Model of PTSD Along With Restoring Glutamatergic Alterations and Dendritic Atrophy in the Prefrontal Cortex

  2022cites this paper